Dompé to acquire Italian ophthalmology company
In January 2011, Dompé has acquired 49% stake in Anabasis and also patent rights for the use of NGF to treat neurotrophic keratitis (NK). Dompé will become the
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).